Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPO Year: 2021
Exchange: NASDAQ
Website: centurytx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2024 | $6.00 | Buy | Rodman & Renshaw |
| 8/28/2023 | $28.00 → $5.00 | Overweight → Neutral | JP Morgan |
| 12/27/2022 | $19.00 | Buy | Chardan Capital Markets |
| 10/31/2022 | $15.00 | Buy | Guggenheim |
| 10/10/2022 | $28.00 | Buy | Canaccord Genuity |
| 5/23/2022 | $27.00 | Buy | H.C. Wainwright |
| 5/12/2022 | Mkt Perform | William Blair | |
| 11/19/2021 | $33.00 → $32.00 | Outperform | SVB Leerink |
| 7/13/2021 | $34.00 | Buy | BofA Securities |
| 7/13/2021 | $33.00 | Outperform | SVB Leerink |
– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy – – Overall response rate (ORR) of 83% observed at CNTY-101 Dose Level 3B alongside a favorable safety profile in patients with r/r B-cell lymphomas in Phase 1 ELiPSE-1 study – – CNTY-101 shows persistence upon repeated cell dosing at Dose Level 3B, consistent with the anticipated protective activity of Century's proprietary Allo-Evasion™ technology – – Ended third quarter 2024 with cash, cash equivalents, and investments of $244.7 million; organizational efficiencies extend expected cash runway into second half of 2026 – PHILADELPH
– Company to share preclinical data across diverse pipeline of iNK, γδ iT, and αβ iT cell therapy programs for oncology and autoimmune disease (AID) – – Preclinical data on development of iPSC-derived CD4+ and CD8+ CAR T cells that demonstrate function comparable to primary αβ CAR-T cells, allowing for control of tumors in vivo without the need for exogenous or engineered cytokines – – Posters include demonstration of advances in gene editing and transgene design that enable greater control and improved functionality of iPSC derived immune cells – PHILADELPHIA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pl
PHILADELPHIA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced that Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, and Chad Cowan, Ph.D., Chief Scientific Officer, will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 9:30am ET. A live webcast of the event can be accessed on the "Events & Presentations" page in the "Investors" section of the Company's website at https://investors.centurytx.com/events-and-presentations. A r
- Morgan Conn, Ph.D., seasoned biotech executive with expertise in financing, business development, and corporate strategy, appointed as Chief Financial Officer - - Chad Cowan, Ph.D., cell therapy pioneer, founder, and former CEO of Clade Therapeutics, appointed as Chief Scientific Officer - - Hy Levitsky, M.D., President of Research and Development, to transition to an advisor to Century - PHILADELPHIA, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune disease, today announced the appointments of Morgan Conn, Ph.D., as
– Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis patients – – Presented interim results from Phase 1 ELiPSE-1 trial of CNTY-101 demonstrating encouraging preliminary efficacy and tolerability data in heavily pretreated relapsed/refractory – – Completed dose escalation for ELiPSE-1 and advancing into dose expansion in 2H 2024 – – Ended second quarter 2024 with cash, cash equivalents, and investments of $269.6 million; Cash runway expected into 2026 – PHILADELPHIA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ:I
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels Novel cell-free DNA method for detecting total body PK suggests CNTY-101 persists outside the bloodstream Enrollment continues in dose escalation phase of ELiPSE-1 at dose levels 3B (three weekly infusions of 1 billion cells) and 4A (single infusion of 3 billion cells) per cycle PHILADELPHIA, June 03, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem
In vitro data showcases CNTY-101's ability to induce CD19-specific cytolysis of B-cells and potential to treat B-cell driven autoimmune diseases including systemic lupus erythematosus (SLE)Preclinical data demonstrates potential utility of using a synthetic ligand targeting CD300a as a universal strategy for preventing NK mediated rejection in allogeneic cell therapies PHILADELPHIA, May 10, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced two poster presentations at the ASGCT 27th Annual Meeting.
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Phase 1 ELiPSE-1 trial in relapsed/refractory (R/R) B-cell lymphoma to be presented at American Society for Clinical Oncology (ASCO) Annual Meeting - Ended 1Q24 with cash, cash equivalents, and invest
PHILADELPHIA, April 23, 2024 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that members of the management team will participate in a virtual fireside chat and panel at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, details of the presentations are as follows: Fireside Chat on Tuesday, April 30, 2024, at 1:30pm ETPanel titled "iPSCs Unleashed: Mastering Manufacturing for Next-Gen Cell Therapies" on Tuesday, April 30, 2024, at 3:30pm ET A replay of the events wi
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile Private placement of $60 million led by Bain Capital Life Sciences supports expansion in autoimmune disease; Reinforcing cash runway into 2026 Acquisition of Clade Therapeutics strengthens Century's position as a leader in allogeneic, iPSC-derived cell therapy through enhancement of pipeline and next generation Allo-EvasionTM platform Newly expanded pipeline incorporates three additional preclinical-stage programs from Clade's αβ iT pla
SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi
- Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™ may support a multi-dosing regimen without the need for continued lymphodepletion - - Received investigational new drug (IND) clearance for CNTY-101 for the treatment of systemic lupus erythematosus (SLE); On track to initiate Phase 1 CALiPSO-1 clinical trial in the first half of 2024 - - Six posters to be presented at upcoming AACR Annual Meeting 2024 highlighting Century's end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein en
- Accomplished leader with over 20 years of broad-ranging experience across the healthcare industry - Brent Pfeiffenberger, Pharm.D., MBA PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer and member of the Board, effective December 4, 2023. A proven leader with over 20 years of global experience across the healthcare industry, Dr. Pfeiffenberger most recently served as Chief Operating Officer at Neogene Therapeutics, a who
– Preclinical data supporting selection of CNTY-101 as lead product candidate presented at AACR Annual Meeting – – Company remains on track to report initial data from Schedule A of the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas by year end – – Ended first quarter 2023 with cash, cash equivalents, and investments of $334.8 million; Cash runway expected into 2026 – PHILADELPHIA, May 11, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ:IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and
– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer – – Michael C. Diem, M.D., promoted to Chief Financial Officer – – Hy Levitsky, M.D., rejoins as President of Research and Development – PHILADELPHIA, April 12, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Greg Russotti, Ph.D., as ad-interim Chief Executive Officer, effective April 11, 2023. Dr. Russotti, who has served as
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell malignancies expected to begin imminently - - Ended third quarter 2022 with cash, cash equivalents, and investments of $395.3 million; Cash runway into 2025 – - Company to host virtual Research and Development Day on Friday, November 11 at 8:00 AM ET - PHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We made steady progre
PHILADELPHIA, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the appointment of Daphne Quimi and Timothy Walbert to the Company's Board of Directors. Ms. Quimi is currently Chief Financial Officer of Amicus Therapeutics and brings experience in public accounting and financial reporting to Century. Mr. Walbert is currently Chairman, President, and Chief Executive Officer of Horizon Therapeutics, and brings expertise in product portfolio building and commercialization. In conjunction with these new appointments, Century also ann
- SEC Filing
Piper Sandler analyst Edward Tenthoff maintains Century Therapeutics (NASDAQ:IPSC) with a Overweight and raises the price target from $9 to $12.
Across the recent three months, 5 analysts have shared their insights on Century Therapeutics (NASDAQ:IPSC), expressing a variety of opinions spanning from bullish to bearish. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 2 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $13.6, a high estimate of $24.00, and a low estimate of $9.00. A
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Century Therapeutics (NASDAQ:IPSC) with a Buy and maintains $11 price target.
In ongoing dose escalation, CNTY-101 has demonstrated a manageable safety profile with no observed DLTs or GvHD and with majority of patients treated in outpatient setting. Encouraging preliminary efficacy in heavily pretreated R/R NHL at initial dose levels. Novel cell-free DNA method for detecting total body PK suggests CNTY-101 persists outside the bloodstream. Enrollment continues in dose escalation phase of ELiPSE-1 at dose levels 3B (three weekly infusions of 1 billion cells) and 4A (single infusion of 3 billion cells) per cycle.
HC Wainwright & Co. analyst Mitchell Kapoor maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target from $13 to $11.
Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.52) by 13.46 percent. This is a 15.09 percent increase over losses of $(0.53) per share from the same period last year. The company reported quarterly sales of $855.000 thousand which missed the analyst consensus estimate of $1.262 million by 32.25 percent. This is a 50.29 percent decrease over sales of $1.720 million the same period last year.
Piper Sandler analyst Edward Tenthoff reiterates Century Therapeutics (NASDAQ:IPSC) with a Overweight and lowers the price target from $10 to $9.
Thursday, Century Therapeutics (NASDAQ:IPSC) unveiled plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications. CNTY-101 is currently being evaluated in a clinical trial in B-cell malignancies (ELiPSE-1) as well as a planned trial in systemic lupus erythematosus (SLE) (CALiPSO-1), which is on track to be initiated in the first half of 2024. Century Therapeutics plans to pursue additional autoimmune disease indication regulatory filings in 2024. The company announced a $60 million private placement to support Century Therapeutics’ increased R&D activities in autoimmune diseases. Centu
Rodman & Renshaw initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $6.00
JP Morgan downgraded Century Therapeutics from Overweight to Neutral and set a new price target of $5.00 from $28.00 previously
Chardan Capital Markets initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $19.00
Guggenheim initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $15.00
Canaccord Genuity initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $28.00
H.C. Wainwright initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $27.00
William Blair initiated coverage of Century Therapeutics with a rating of Mkt Perform
SVB Leerink reiterated coverage of Century Therapeutics with a rating of Outperform and set a new price target of $32.00 from $33.00 previously
BofA Securities initiated coverage of Century Therapeutics with a rating of Buy and set a new price target of $34.00
SVB Leerink initiated coverage of Century Therapeutics with a rating of Outperform and set a new price target of $33.00
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13D/A - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G - Century Therapeutics, Inc. (0001850119) (Subject)
SC 13G/A - Century Therapeutics, Inc. (0001850119) (Subject)
8-K - Century Therapeutics, Inc. (0001850119) (Filer)
10-Q - Century Therapeutics, Inc. (0001850119) (Filer)
8-K - Century Therapeutics, Inc. (0001850119) (Filer)
8-K - Century Therapeutics, Inc. (0001850119) (Filer)
10-Q - Century Therapeutics, Inc. (0001850119) (Filer)
8-K - Century Therapeutics, Inc. (0001850119) (Filer)
EFFECT - Century Therapeutics, Inc. (0001850119) (Filer)
8-K/A - Century Therapeutics, Inc. (0001850119) (Filer)
424B3 - Century Therapeutics, Inc. (0001850119) (Filer)
8-K - Century Therapeutics, Inc. (0001850119) (Filer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
3 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
3 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
4 - Century Therapeutics, Inc. (0001850119) (Issuer)
- Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Phase 1 ELiPSE-1 trial in relapsed/refractory (R/R) B-cell lymphoma to be presented at American Society for Clinical Oncology (ASCO) Annual Meeting - Ended 1Q24 with cash, cash equivalents, and invest
– Data presented at 65th ASH Annual Meeting show CNTY-101 was generally well tolerated at Dose Level 1 (100 million cells) in a high-risk, heavily pretreated R/R B-cell lymphoma patient – – Preliminary clinical data demonstrate six-month durable complete response in Dose Level 1 in a single patient following multiple cycles of CNTY-101 without lymphodepletion – – Pharmacokinetic data suggests CNTY-101 exposure may be maintained upon administration of additional cycles without lymphodepletion due to lack of observed allo-rejection – – Company to host conference call on Monday, December 11 at 7:30 AM PT/10:30 AM ET to review ASH data including additional clinical results from Dose Level 1
PHILADELPHIA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ:IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that it will host a conference call and live audio webcast on Monday, December 11 at 7:30 AM PT/ 10:30 AM ET to discuss initial clinical data supporting a multi-dosing strategy from its ongoing first-in-human Phase 1 ELiPSE-1 trial of CNTY-101, the Company's lead allogeneic, iPSC-derived CAR-iNK cell therapy, in relapsed/refractory CD19 positive B-cell lymphomas. In addition to updated preliminary clinical data as of a more re
Reports Fourth Quarter Revenues of $12.0 Billion; Full-Year Revenues of $46.4 Billion Posts Fourth Quarter Earnings Per Share of $1.07 and Non-GAAP EPS of $1.83; Posts Full-Year Earnings Per Share of $3.12 and Non-GAAP EPS of $7.51 Delivers Strong Revenues for Eliquis, Immuno-Oncology and New Product Portfolios Advances Pipeline with Achievement of Significant Clinical and Regulatory Milestones; Builds Strong Foundation for Portfolio Renewal Announces $15 Billion Share Repurchase Authorization; $5 Billion Accelerated Share Repurchase Agreement to be Executed During the First Quarter 2022 Provides GAAP and More Detailed Non-GAAP Financial Guidance for 2022 Reaffirms Long-term Fi